Zusammenfassung
Hintergrund: In Fällen therapieresistenter Schizophrenie werden zunehmend oft atypische Antipsychotika kombiniert. Methodik: Wir berichten über einen schizophrenen Patienten, dessen Erkrankung sich gegenüber Olanzapin, Risperidon und Quetiapin resistent erwies, unter Clozapin aber teilremittierte. Weil Nebenwirkungen die Zuverlässigkeit der Einnahme gefährdeten, wurde mit Ziprasidon augmentiert. Ergebnisse: Positiv- und Negativsymptomatik wurden gut kontrolliert, trotz einer transienten Hyperprolaktinämie war die subjektive Zufriedenheit sehr hoch. Diskussion: Die berichtete Kombinationsbehandlung erscheint neurobiologisch sinnvoll, kann Nebenwirkungen reduzieren und sollte hinsichtlich Nutzen und Risiken mit prospektiven Studien untersucht werden.
Abstract
Objectives: In cases of treatment-resistant schizophrenic psychoses combined application of atypical antipsychotic drugs is an often-used strategy. Method: We report the case of a 35-year old man with paranoid schizophrenia, whose symptoms turned out to be resistant to the application of olanzapine, risperidone and quetiapine. After switch to clozapine paranoid delusions remitted, but schizophrenic negative symptoms persisted and side effects limited the patient's compliance. Augmentation with ziprasidone allowed a reduction of the clozapine dose and ameliorated the affective deficits. Results: Positive and negative symptoms were well controlled. In spite of a transient hyperprolactinaemia and sexual dysfunction the patient was highly content. Discussion: The combined application of ziprasidone and clozapine follows a neurobiological rationale, seems able to reduce side effects, and should be further evaluated with respect to risk and benefit in prospective studies.
Literatur
-
1
Hellewell J S.
Treatment-resistant schizophrenia: reviewing the options and identifying the way forward.
J Clin Psychiatry.
1999;
60, Suppl 23
14-19
-
2
Buchanan R W.
Clozapine: efficacy and safety.
Schizophr Bull.
1995;
21 (4)
579-591
-
3
Miller D D.
Review and management of clozapine side effects.
J Clin Psychiatry.
2000;
61, Suppl 8
14-17, discussion 18 - 19
-
4
Freudenreich O, Goff D C.
Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations.
Acta Psychiatr Scand.
2002;
106
323-330
-
5
Caley C F, Cooper C K.
Ziprasidone: the fifth atypical antipsychotic.
Ann Pharmacother.
2002;
36 (5)
839-851
-
6
Seeger T F, Seymour P A, Schmidt A W, Zorn S H, Schulz D W, Lebel L A, McLean S, Guanowsky V, Howard H R, Lowe J A.
Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity.
J Pharmacol Exp Ther.
1995;
275 (1)
101-113
-
7
Prakash C, Kamel A, Anderson W, Howard H.
Metabolism and excretion of the novel antipsychotic drug ziprasidone in rats after oral administration of a mixture of 14C- and 3H-labeled ziprasidone.
Drug Metabol Disp.
1997;
25 (2)
206-218
-
8
Kaye N S.
Ziprasidone augmentation of clozapine in 11 patients.
J Clin Psychiatry.
2003;
64 (2)
215-216
-
9
Kay S R, Fiszbein A, Opler L A.
The positive and negative syndrome scale (PANSS) for schizophrenia.
Schizophr Bull.
1987;
13
261-276
-
10
Stahl S M.
Antipsychotic polypharmacy: squandering precious recources?.
J Clin Psychiatry.
2002;
63 (2)
93-94
-
11
Kar L D Van de, Rittenhouse P A, Li Q, Levy A D.
Serotonergic regulation of renin and prolactin secretion.
Beh Brain Res.
1996;
73 (1 - 2)
203-208
-
12
Remington G, Kapur S.
Atypical antipsychotics: are some more atypical than others?.
Psychopharmacol.
2000;
148 (1)
3-15
-
13
Petty R G.
Prolactin and antipsychotic medications: mechanism of action.
Schizophr Res.
1999;
35, Suppl
67-73
-
14
Compton M T, Miller A H.
Antipsychotic-induced hyperprolactinemia and sexual dysfunction.
Psychopharmacol Bull.
2002;
36 (1)
143-164
-
15
Miceli J J, Wilner K D, Hansen R A, Johnson A C, Apseloff G, Gerber N.
Single- and multiple-dose pharmacokinetics of ziprasidone under non-fasting conditions in healthy male volunteers.
Br J Clin Pharmacol.
2000;
49, Suppl 1
5S-13S
Dr. med. Mathias Zink
Central Institute of Mental Health
P.O. Box: 12 21 20
68072 Mannheim
eMail: zink@kv.zi-mannheim.de
